Decreases in hereditary angioedema attack rates seen with daily oral deucrictibant at 13 weeks stayed at a low level for up to 34 months, according to open-label extension study results.These data on ...
Woman's World on MSN
Ozempic 2.0! Experts call GLP-1 pills a game-changer for weight loss—here's how they work and when to expect them
Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...
Eggs are often considered as a superfood rich in protein and other necessary nutrients. From weight loss to boosting ...
For adults with atopic dermatitis, rocatinlimab treatment yields significant improvements across clinical end points, ...
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) ...
The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemotherapy in advanced ESCC, showing a mOS of 17.7 months and a 3-year OS rate of 29.7%.
The road to creating a blue LED was long and rough, but in 1993, it burst onto the scene. Learn about the struggles and ...
GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging ...
Adding lumateperone (Caplyta; Johnson & Johnson) to ongoing antidepressant therapy (ADT) significantly improved depression severity in adults with major depressive disorder (MDD) who had not responded ...
Collection of eight posters include analyses of data from studies of diazepam nasal spray in treatment of episodes of ...
With the 2025 American Society of Hematology (ASH) Meeting & Exposition kicking off on Saturday, December 6, in Orlando, Florida, Targeted Oncology is bringing you background on the most exciting ...
Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback